There were 91 pediatric patients aged 2 months to 15 years in the first study described above. Clinical efficacy rates at end of therapy in the evaluable populations were 78% for mupirocin ointment (n=42) and 36% for vehicle placebo (n=49). In the second study described above, all patients were pediatric except two adults in the group receiving mupirocin ointment. The age range of the pediatric patients was 7 months to 13 years.
The clinical efficacy rate for mupirocin ointment (n=27) was 96%, and for erythromycin it was unchanged (78.5%).
Mupirocin Ointment USP, 2% is supplied
NDC 54868-4958-0 22 gram tube
Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].
*Bactroban® Nasal is a registered trademark of SmithKline Pharmaceuticals.
E. FOUGERA & CO.
A division of Nycomed US Inc.
MELVILLE, NEW YORK 11747
Physicians Total Care, Inc.
Tulsa, OK 74146
FOUGERA ® Rx only
MUPIROCIN OINTMENT USP, 2%
For dermatologic use only.
Keep out of reach of
NET WT 22 grams
| MUPIROCIN |
|Labeler — Physicians Total Care, Inc. (194123980)|
|Physicians Total Care, Inc.||194123980||relabel|
Revised: 04/2009 Physicians Total Care, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.